indazoles has been researched along with ku 0063794 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beale, GS; Haagensen, EJ; Kyle, S; Maxwell, RJ; Newell, DR | 1 |
| Bressanin, D; Buontempo, F; Chiarini, F; Evangelisti, C; Martelli, AM; McCubrey, JA; Melchionda, F; Pagliaro, P; Pession, A; Ricci, F; Tabellini, G; Tazzari, PL | 1 |
2 other study(ies) available for indazoles and ku 0063794
| Article | Year |
|---|---|
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
Topics: Benzamides; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Humans; Imidazoles; Indazoles; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Quinolines; Signal Transduction; Structure-Activity Relationship; Sulfonamides; TOR Serine-Threonine Kinases | 2012 |
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
Topics: Adult; Caspase 3; Cell Line, Tumor; Child; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; Signal Transduction; Sulfonamides; T-Lymphocytes; TOR Serine-Threonine Kinases | 2012 |